Omar Johnson
Overview
Explore the profile of Omar Johnson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
242
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Berjis A, Muthumani D, Aguilar O, Pomp O, Johnson O, Finck A, et al.
Nat Commun
. 2024 May;
15(1):3937.
PMID: 38729924
Human natural killer (NK) cell-based therapies are under assessment for treating various cancers, but cryopreservation reduces both the recovery and function of NK cells, thereby limiting their therapeutic feasibility. Using...
2.
Zhang C, Kadu S, Xiao Y, Johnson O, Kelly A, OConnor R, et al.
Cancer Immunol Res
. 2023 Aug;
11(11):1524-1537.
PMID: 37649085
Natural killer (NK) cells are frequently expanded for the clinic using irradiated, engineered K562 feeder cells expressing a core transgene set of membrane-bound (mb) IL15 and/or mbIL21 together with 41BBL....
3.
Exploiting the CD200-CD200R immune checkpoint axis in multiple myeloma to enhance CAR T-cell therapy
Tang Y, Liu W, Kadu S, Johnson O, Hasanali Z, Kelly A, et al.
Blood
. 2023 Aug;
143(2):139-151.
PMID: 37616575
Patients with multiple myeloma (MM) treated with B-cell maturation antigen (BCMA)-specific chimeric antigen receptor (CAR) T cells usually relapse with BCMA+ disease, indicative of CAR T-cell suppression. CD200 is an...
4.
Mai D, Johnson O, Reff J, Fan T, Scholler J, Sheppard N, et al.
Proc Natl Acad Sci U S A
. 2023 Mar;
120(12):e2218632120.
PMID: 36920923
A fundamental limitation of T cell therapies in solid tumors is loss of inflammatory effector functions, such as cytokine production and proliferation. Here, we target a regulatory axis of T...
5.
Chudal L, Pandey N, Phan J, Johnson O, Lin L, Yu H, et al.
ACS Appl Bio Mater
. 2022 Jan;
3(3):1804-1814.
PMID: 35021670
Herein, for the first time, we report copper-cysteamine (Cu-Cy) nanoparticles having Cu instead of Cu as an efficient heterogeneous Fenton-like catalyst for highly selective cancer treatment. Initial measurements of Cu-Cy's...
6.
Tischfield D, Gurevich A, Johnson O, Gatmaytan I, Nadolski G, Soulen M, et al.
Radiology
. 2022 Jan;
303(1):215-225.
PMID: 35014906
Background Transarterial embolization (TAE) is the most common treatment for hepatocellular carcinoma (HCC); however, there remain limited data describing the influence of TAE on the tumor immune microenvironment. Purpose To...
7.
Perkons N, Johnson O, Pilla G, Gade T
NMR Biomed
. 2021 Mar;
34(6):e4502.
PMID: 33772910
This study investigates the in vivo pharmacokinetics and pharmacodynamics of hyperpolarized [1- C]-pyruvate in a translational cancer model in order to inform the application of dynamic nuclear polarization (DNP)-enhanced magnetic...
8.
Park B, Perkons N, Profka E, Johnson O, Morley C, Appel S, et al.
J Vasc Interv Radiol
. 2020 Aug;
31(10):1612-1618.e1.
PMID: 32826152
Purpose: To evaluate the utility of visualizing preprocedural MR images in 3-dimensional (3D) space using augmented reality (AR) before transarterial embolization of hepatocellular carcinoma (HCC) in a preclinical model. Materials...
9.
Perkons N, Johnson O, Pilla G, Profka E, Mercadante M, Ackerman D, et al.
Clin Cancer Res
. 2020 Jun;
26(17):4581-4589.
PMID: 32499234
Purpose: Targeted therapies for cancer have accelerated the need for functional imaging strategies that inform therapeutic efficacy. This study assesses the potential of functional genetic screening to integrate therapeutic target...
10.
Zhen X, Chudal L, Pandey N, Phan J, Ran X, Amador E, et al.
Mater Sci Eng C Mater Biol Appl
. 2020 Mar;
110:110659.
PMID: 32204087
Herein, for the first time, we demonstrate that the combination of copper-cysteamine (Cu-Cy) nanoparticles (NPs) and potassium iodide (KI) can significantly inactivate both Gram-positive MRSA and Gram-negative E. coli. To...